Loading
Life sciences · Journal article
Children · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Obstructive sleep apnea (OSA) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist in children with obesity, but data on hepatic outcomes following OSA treatment are limited. This study evaluated associations between targeted OSA treatment and longitudinal changes in sleep-disordered breathing and hepatic outcomes. Methods: This retrospective observational cohort included children aged 4–18 years with obesity, polysomnography-confirmed OSA, and ultrasonography-confirmed MASLD who received clinical care between 2018 and 2025. Children received targeted OSA treatment (adenotonsillectomy and/or continuous positive airway pressure [CPAP]) or non-targeted treatment. Polysomnographic parameters, liver enzymes, and ultrasonographic hepatic steatosis were assessed at baseline and 6–12 months. The primary outcome was a ≥30% reduction in alanine aminotransferase (ALT). Results: Among 127 children, 67 received targeted treatment and 60 did not. Targeted treatment was associated with improvements in OSA severity, nocturnal oxygenation, ALT, AST, and ultrasonographic steatosis, whereas less favorable trajectories occurred without targeted treatment. ALT reduction differed significantly among treatment modalities, with the greatest reduction observed with CPAP. In multivariable analyses, CPAP was associated with both ≥30% ALT reduction (OR 14.54, 95% CI 3.87–54.69; p < 0.01) and ultrasonographic improvement (OR 3.33, 95% CI 1.16–9.59; p = 0.03). A BMI z-score reduction of ≥0.25 was not independently associated with either hepatic outcome. Conclusions: Targeted OSA treatment was associated with more favorable sleep and hepatic outcomes, with the strongest associations observed for CPAP. Prospective studies are needed to determine whether these associations represent causal treatment effects.